Major clinical research advances in gynecologic cancer in 2020

Abstract

In 2020 series, we summarized the major clinical research advances in gynecologic oncology with providing representative figures of the most influential study for 1 of each 3 gynecologic cancers: cervix, ovary, and uterine corpus. Review for cervical cancer covered targeted agents and immune checkpoint inhibitors, adjuvant radiation therapy or concurrent/sequential chemoradiation therapy after radical hysterectomy in early cervical cancer, radical surgery in early cervical cancer; and prevention and screening. Ovarian cancer research included studies of various combinations of poly (ADP-ribose) polymerase inhibitors with chemotherapy, immune checkpoint inhibitors, and/or vascular endothelial growth factor inhibitors according to the clinical setting. For uterine corpus cancer, molecular classification upon which the decision of adjuvant treatments might be based, World Health Organization recommendation of 2-tier grading system (low grade vs. high grade), sentinel lymph node assessment and ovarian preservation in clinically early-stage endometrial cancer were reviewed. Molecular targeted agents including immune checkpoint inhibitors which showed promising anti-tumor activities in advanced/recurrent endometrial cancer were also included in this review.

Prognostic Model for Predicting Overall and Cancer-Specific Survival Among Patients With Cervical Squamous Cell Carcinoma: A SEER Based Study

“…In addition, there is evidence that patients receiving concurrent chemoradiotherapy had better prognosis and higher OS compared with radiotherapy alone, both in early (62)(63)(64) and advanced (65-67) stages. At the same time, some studies have shown that preoperative or postoperative combination chemoradiotherapy, neoadjuvant chemotherapy or immunotherapy can improve patient progression-free and overall survival (62,63,66,(68)(69)(70)(71)(72)(73)(74)(75)(76)(77). Despite these harmful effects, radiotherapy is still an effective treatment for CSCC.…”

Homologous Recombination Deficiency Associated With Response to Poly (ADP-ribose) Polymerase Inhibitors in Ovarian Cancer Patients: The First Real-World Evidence From China

“…PARPi has changed the treatment pattern of ovarian cancer. Many clinical trials and real-world studies have confirmed that PARPi can significantly prolong the PFI of patients with ovarian cancer (3)(4)(5)(6).…”

Analysis of the Correlation between Nutritional Status and Quality of Life of Patients with Gynaecological Ovarian Cancer during Postoperative Chemotherapy

“…The ovarian cancer study reviewed focused on pharmaceuticals and immunological circuit blockers, postoperative radiotherapy or multiple simultaneous chemotherapy, and radiation therapy after laparoscopic procedure in precancerous cervical cancer, severe operation in precancerous cervical cancer, and prophylaxis and monitoring. [ 26 ].…”